AGTC NASDAQ
Alachua, FL 32615
US
Applied Genetic Technologies Corporation, a clinical-stage biotechnology company, develops transformational genetic therapies for patients suffering from rare and debilitating diseases. Its advanced product candidates include three ophthalmology development programs across two targets, including X-linked retinitis pigmentosa, which is in the Phase 1/2 clinical trials; and achromatopsia that is in Phase 1/2 clinical trials. It is also developing an optogenetic product candidate to treat advanced retinal disease. In addition, the company has initiated one preclinical program in otology; preclinical program in dry age-related macular degeneration; and two preclinical programs in targeting central nervous system disorders, including frontotemporal dementia and amyotrophic lateral sclerosis. It has collaboration agreements with University of Florida; Bionic Sight, Inc.; and Otonomy, Inc. The company was incorporated in 1999 and is headquartered in Alachua, Florida.
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Robinson James A. Jr | D-Return | 25,000 | — | 2022-11-30 |
| VANLENT ANNE | D-Return | 14,000 | — | 2022-11-30 |
| Rosen James | U-Tender | 1,000 | — | 2022-11-30 |
| Rosen James | D-Return | 14,000 | — | 2022-11-30 |
| Aliski William | U-Tender | 8,500 | — | 2022-11-30 |